BioNTech SE announces trial results
- AHEAD-MERIT Phase 2/3 trial did not meet PFS endpoint
- Trial continues to evaluate OS endpoint
- BNT113 targets HPV16+ head and neck cancer
Every EDGAR filing for BioNTech SE (BNTX), newest first, with AI summaries and stories.
No open-market insider buys in the last 30 days.
Also: 15 open-market sales ($47.8M).
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
Ugur Sahin, reporting
Ugur Sahin, reporting
Ugur Sahin, reporting
Ugur Sahin
Ugur Sahin, insider filing for BNTX
Ugur Sahin, reporting
Ugur Sahin, insider filing for BNTX
Ugur Sahin, reporting
Ugur Sahin, insider filing for BNTX
Ugur Sahin, reporting
Ugur Sahin, insider filing for BNTX
Ugur Sahin, reporting
Ugur Sahin, insider filing for BNTX
Ugur Sahin, reporting
Ugur Sahin, insider filing for BNTX
Ugur Sahin, reporting
Ugur Sahin, insider filing for BNTX
Ugur Sahin, reporting
Ugur Sahin, insider filing for BNTX
Ugur Sahin, reporting
Ugur Sahin, insider filing for BNTX
Ugur Sahin, reporting
Ugur Sahin, insider filing for BNTX
Ugur Sahin, reporting
Medine GmbH, planned sale of BNTX shares
Medine GmbH, reporting
Iris Katharina Low-Friedrich, new insider at BNTX
Iris Katharina Low-Friedrich, reporting
Ownership stake disclosure by Ugur Sahin (amended)
Ugur Sahin, filed by
Ownership stake disclosure by Kg Athos (amended)
Kg Athos, filed by
Gomez Ramon Zapata, insider filing for BNTX
Gomez Ramon Zapata, reporting
Medine GmbH, planned sale of BNTX shares
Medine GmbH, reporting
Sierk Poetting, insider filing for BNTX
Sierk Poetting, reporting
Ugur Sahin, new insider at BNTX (amended)
Ugur Sahin, reporting
Nicola Claire Blackwood, new insider at BNTX
Nicola Claire Blackwood, reporting